Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

NCT01959633 is registered in ClinicalTrials.gov with Fondazione Melanoma Onlus as lead sponsor.

NCT NCT01959633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01959633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
Lead sponsor
Fondazione Melanoma Onlus
Phase
Phase 1/2
Overall status
Completed
Start date
April 3, 2014
Completion date
March 26, 2018
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma